Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Delforge, Michel" or (type exact bookEditor and editor="Delforge, Michel")

Add to list
- Journal Article
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

Torben Plesner, Simon J. Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Vangsted, Jane Estell, Michel Delforge, Fritz Offner (UGent) , Patrick Twomey, et al.

(2023) Clinical Hematology International. 5(1). p.43-51
Add to list
- Journal Article
- A1
- open access
Selinexor, bortezomib and dexamethasone : an effective salvage regimen for heavily pretreated myeloma patients

Michel Delforge, Jolien Raddoux, Corine Antonis, Celine Clement, Nicolas Kint (UGent) , Anneleen Vanhellemont, Julie Bravetti and Peter Vandenberghe

(2022) ONCOTARGETS AND THERAPY. 15. p.243-250
Add to list
- Conference Paper
- C3
CARTITUDE-2 cohort B : efficacy and safety of ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy directed against B-cell maturation antigen, in patients with multiple myeloma and early relapse after initial treatment

Niels W. C. J. Van de Donk, Michel Delforge, Mounzer Agha, Adam D. Cohen, Yael C. Cohen, Jens Hillengass, Sebastien Anguille, Tessa Kerre (UGent) , Wilfried Roeloffzen, Jordan M. Schecter, et al.

(2022) BRITISH JOURNAL OF HAEMATOLOGY. In British Journal of Haematology 197(supplement 1). p.118-119
Add to list
- Journal Article
- A1
Immunomodulators in newly diagnosed multiple myeloma : current and future concepts

Michel Delforge, Sophie Vlayen and Nicolas Kint (UGent)

(2021) EXPERT REVIEW OF HEMATOLOGY. 14(4). p.365-376
Add to list
Compass : a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients

Michel Delforge, Jolien Raddoux, Cindy Kenis, Anneleen Vanhellemont, Philippe Mineur, Ellen Hoornaert, Ka Lung Wu, Jo Caers, Koen Van Eygen, Alain Kentos, et al.

(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 2). p.S124-S124
Add to list
- Journal Article
- A1
- open access
Quality of life analyses in patients with multiple myeloma : results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay Nooka, et al.

(2021) BMC CANCER. 21(1).
Add to list
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Bene, Sonja Zweegman, Helene Caillon, Denis Caillot, et al.

(2021) LANCET ONCOLOGY. 22(10). p.1378-1390
Add to list
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou, Ajay K. Nooka, Andrew J. Yee, Carol A. Huff, Philippe Moreau, David Dingli, Craig Cole, Sagar Lonial, et al.

(2019) NEW ENGLAND JOURNAL OF MEDICINE. 381(8). p.727-738
Add to list
- Conference Paper
- C3
Darbepoetin alfa for the treatment of anemic patients with myelodysplastic syndrome : a Belgian single-arm, companion trial to the Arcade phase 3 study

Michel Delforge, Dominiek Mazure (UGent) , Isabelle Vande Broek, Jo Caers, Sejal Badre, Bhakti Mehta and Cisio De Oliveira Brandao

(2017) BLOOD. 130(suppl. 1).
Add to list
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

Gareth Morgan, Antonio Palumbo, Sujith Dhanasiri, Dawn Lee, Katja Weisel, Thierry Facon, Michel Delforge, Albert Oriol, Mohamed Zaki, Xin Yu, et al.

(2015) BRITISH JOURNAL OF HAEMATOLOGY. 168(6). p.820-823
Add to list
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

Michel Delforge, Dominik Selleslag, Yves Beguin, Agnès Triffet, Philippe Mineur, Koen Theunissen, Carlos Graux, Fabienne Trullemans, Dominique Boulet, Koen Van Eygen, et al.

(2014) LEUKEMIA RESEARCH. 38(5). p.557-563
Add to list
Neutrophil extracellular trap cell death requires both autophagy and superoxide generation

Quinten Remijsen (UGent) , Tom Vanden Berghe (UGent) , Ellen Wirawan, Bob Asselbergh (UGent) , Eef Parthoens (UGent) , Riet De Rycke (UGent) , Samuel Noppen (UGent) , Michel Delforge, Jean Willems and Peter Vandenabeele (UGent)

(2011) CELL RESEARCH. 21(2). p.290-304
Add to list
- Journal Article
- A1
- open access
Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study

Kristel Van Calsteren, René Verbesselt, Nelleke Ottevanger, Michael Halaska, Liesbeth Heyns, Rieta Van Bree, Ernst de Bruijn, Daniel Chai, Michel Delforge, Lucien Noens (UGent) , et al.

(2010) ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 89(10). p.1338-1345

Academic Bibliography

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

Selinexor, bortezomib and dexamethasone : an effective salvage regimen for heavily pretreated myeloma patients

CARTITUDE-2 cohort B : efficacy and safety of ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy directed against B-cell maturation antigen, in patients with multiple myeloma and early relapse after initial treatment

Immunomodulators in newly diagnosed multiple myeloma : current and future concepts

Compass : a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients

Quality of life analyses in patients with multiple myeloma : results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

Oral selinexor-dexamethasone for triple-class refractory multiple myeloma

Darbepoetin alfa for the treatment of anemic patients with myelodysplastic syndrome : a Belgian single-arm, companion trial to the Arcade phase 3 study

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

Neutrophil extracellular trap cell death requires both autophagy and superoxide generation

Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study

Contents

Support

Contact